Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tocilizumab Treatment in Patients With COVID-19
Sponsor: Instituto Nacional de Cancerologia de Mexico
Summary
A phase II clinical trial will be carried out with the objective of studying the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection. Due to the high mortality of severe forms of SARS-CoV-2 and for ethical reasons, a control arm will not be included. Patients will be recruited by signing an informed consent and the baseline variables of interest will be recorded. Tocilizumab will be administered in one or two doses, depending on the case, and will be followed up for 30 days. The response to treatment, survival and evolution will be studied. Factors associated with improvement of ARDS and survival will be identified through multivariate analyzes. The results will be compared with those reported internationally.
Official title: Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-06-01
Completion Date
2027-12-31
Last Updated
2026-04-09
Healthy Volunteers
Yes
Conditions
Interventions
Tocilizumab 20 MG/ML
We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
Locations (1)
National Cancer Institute of Mexico
Mexico City, Mexico City, Mexico